1 week Ago By Defense World Staff
Precigen, Inc. ( NASDAQ:PGEN – Free Report ) – Equities researchers at HC Wainwright reduced their FY2026 earnings per share estimates for shares of Precigen in a note issued to investors on Thursday, January 23rd. HC Wainwright analyst S.
Ramakanth now anticipates that the biotechnology company will earn ($0.01) per share for the year, down from their prior forecast of $0.01.
HC Wainwright currently has a “Buy” rating and a $6.00 price target on the stock. The consensus estimate for Precigen’s current full-year earnings is ($0.
33) per share. HC Wainwright also issued estimates for Precigen’s FY2027 earnings at $0.20 EPS and FY2029 earnings at $0.
62 EPS. Separately, JMP Securities reissued a “market outperform” rating and issued a $5.00 price objective on shares of Precigen in a research report on Tuesday, January 14th.
Two equities research analysts have rated the stock with a sell rating and four have assigned a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $7.
00. Precigen Trading Up 3.7 % Shares of PGEN opened at $1.
39 on Friday. The firm has a market capitalization of $407.09 million, a P/E ratio of -2.
53 and a beta of 1.65. The stock’s fifty day simple moving average is $0.
94 and its 200 day simple moving average is $1.06. Precigen has a twelve month low of $0.
65 and a twelve month high of $1.93. Institutional Investors Weigh In On Precigen A number of hedge funds have recently made changes to their positions in the business.
LexAurum Advisors LLC raised its holdings in shares of Precigen by 151.9% during the fourth quarter. LexAurum Advisors LLC now owns 691,544 shares of the biotechnology company’s stock valued at $775,000 after buying an additional 417,055 shares during the last quarter.
SG Americas Securities LLC raised its holdings in Precigen by 27.9% during the fourth quarter. SG Americas Securities LLC now owns 57,641 shares of the biotechnology company’s stock worth $65,000 after purchasing an additional 12,578 shares in the last quarter.
Synovus Financial Corp grew its position in Precigen by 100.0% in the third quarter. Synovus Financial Corp now owns 98,130 shares of the biotechnology company’s stock worth $93,000 after buying an additional 49,065 shares during the last quarter.
Barclays PLC grew its position in Precigen by 190.4% in the third quarter. Barclays PLC now owns 189,353 shares of the biotechnology company’s stock worth $179,000 after buying an additional 124,141 shares during the last quarter.
Finally, Geode Capital Management LLC grew its position in Precigen by 4.8% in the third quarter. Geode Capital Management LLC now owns 3,246,508 shares of the biotechnology company’s stock worth $3,075,000 after buying an additional 149,829 shares during the last quarter.
Institutional investors own 33.51% of the company’s stock. About Precigen ( Get Free Report ) Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases.
It operates through two segments, Biopharmaceuticals and Exemplar. Featured Articles Five stocks we like better than Precigen How to Start Investing in Real Estate Bloom Energy: Powering the Future With Decentralized Energy 2 Fintech Stocks to Buy Now and 1 to Avoid Dividend Powerhouses: Blue-Chip Stocks Built for the Long Haul What Are Treasury Bonds? Why Traders Are Buying the Dip on Johnson & Johnson Stock Receive News & Ratings for Precigen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Precigen and related companies with MarketBeat.com's FREE daily email newsletter .
.
